Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis Pigmentosa

ClinicalTrials.gov ID: NCT00447980

Public ClinicalTrials.gov record NCT00447980. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 5, 2026, 5:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II/III Study of Encapsulated Human NTC-201 Cell Implants Releasing Ciliary Neurotrophic Factor (CNTF) for Participants With Retinitis Pigmentosa Using Visual Field Sensitivity as the Primary Outcome

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to look at the safety and effectiveness of CNTF implants on vision in persons with retinitis pigmentosa, Usher type II \& III, and Choroideremia. This research is being done because there are no effective therapies for people with these retinal degenerations. They are genetic disorders that affect one's ability to see at night, and later cause tunnel vision and loss of central vision. Retinal degenerations affect the retina, a light sensitive layer of cells in the back of the eye. Slowly over time, these cells die and cause permanent loss of vision. The implant is a small capsule that contains human retinal pigment epithelium cells. These cells have been given the ability to make CNTF and release it through the capsule membrane into the surrounding fluid. In this study, two different CNTF dose levels will be used: a high dose and a low dose in one eye, as well as a sham (or placebo) surgery in the other eye.

Study identification

NCT ID
NCT00447980
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Neurotech Pharmaceuticals
Industry
Enrollment
73 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 64 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 21, 2007
Primary completion
Apr 18, 2010
Completion
Apr 18, 2010
Last update posted
Apr 30, 2025

2007 – 2010

United States locations

U.S. sites
12
U.S. states
9
U.S. cities
11
Facility City State ZIP Site status
Retina-Vitreous Associates Medical Group Beverly Hills California 90211
University of Califoria, Davis Sacramento California 95817
University of California, San Francisco San Francisco California 94143-0730
Bascom Palmer Eye Insitute Miami Florida 33101
Kellogg Eye Center Ann Arbor Michigan 48105
University of Minnesota Minneapolis Minnesota 55455-0501
NY University Medical Center New York New York 10016
Casey Eye Institue Portland Oregon 97239-4197
The Hamilton Eye Institute Memphis Tennessee 38163
Retina Foundation of Southwest Dallas Texas 75231
University of Utah Salt Lake City Utah 84112
The University of Utah - John A. Moran Eye Center Salt Lake City Utah 84132

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00447980, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 30, 2025 · Synced Sep 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00447980 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →